Hemsö Becomes an Associated Partner of the Flemingsberg Science Foundation

Flemingsberg, June 13, 2024

The Flemingsberg Science Foundation announces today that the property company Hemsö is becoming an associated partner of the foundation. Through this partnership, Hemsö aligns with the foundation’s purposes and goals.

“Hemsö plays a central role in the development of Campus Flemingsberg, where Novum serves as the hub for various research companies. Now that Hemsö is becoming a partner of the foundation and a part of our initiative ‘Etableringskontoret’* it creates entirely new conditions and opportunities for the foundation to develop the Campus. We are very pleased with the decision and look forward to continuing to develop Flemingsberg together with Hemsö,” says Johnny Högberg, CEO of the Flemingsberg Science Foundation.

In the foundation’s strategic plan for the period 2022-2025, the importance of attracting new partners and stakeholders who share our vision and see the value in investing in both the foundation’s operations and Flemingsberg’s site development is emphasized. Partnerships like these are thus crucial for Flemingsberg’s progress and the pace of its continued development.

“Flemingsberg is the place where academia meets society and industry, what happens here is important for Stockholm and Sweden. Hemsö contributes by owning and developing advanced buildings for education, research, and healthcare, while Flemingsberg Science builds bridges between different stakeholders. By becoming an associate partner, Hemsö aims to take further responsibility to strengthen activities in Flemingsberg and attract more companies and public entities here.” – Anders Lövefors, Project Developer at Hemsö.

The main focus of the partnership will be in line with the foundation’s goal of making Flemingsberg the first choice for establishments in southern Stockholm. Through this partnership, we open up new opportunities to drive projects and initiatives in areas such as site development, packaging, and marketing of Flemingsberg. Additionally, the inclusion of associate partners means an increase in diversity and expertise within the foundation. We continue to actively work to strengthen our partnership with more actors who share our vision of investing in both Flemingsberg’s operations and its future development.

*Etableringskontoret is a place where partners and stakeholders in Flemingsberg meet to increase the pace of establishment in Flemingsberg.

Johnny Högberg
CEO Flemingsberg Science Foundation
070 550 12 73

South Korean Game Investors Visited Press Start Game Hub in Flemingsberg

A delegation of investors from some of South Korea’s leading game companies visited Press Start Game Hub in Flemingsberg yesterday, a growing hub for game innovation and entrepreneurship in Europe. The visit was part of an initiative organized by Business Sweden, aimed at strengthening ties between the Swedish and South Korean gaming industries.

The Flemingsberg Science Foundation welcomes Angela Hoyer as the new Networks and Event Manager

With a background as a researcher at Karolinska Institutet and experience from academia, industry, and networking, Angela Hoyer, the new Networks and Event Manager at the Flemingsberg Science Foundation, is passionate about developing the life science sector. In her new role, Angela looks forward to creating meeting places where collaborations can grow, while also contributing to Flemingsberg’s continued development as a strong international hub for research and innovation.

A national resource for tomorrow’s treatments – Karolinska ATMP Center is now inaugurated

With a clear message of hope for the future and a powerful spirit of collaboration, the Karolinska ATMP Center in Flemingsberg was inaugurated at the end of August. The center is a collaboration between Karolinska Institutet and Karolinska University Hospital and will serve as a national resource for the production of advanced therapies (ATMPs), where research, clinical trials, and treatments work seamlessly together to deliver groundbreaking therapies to patients.

Previous 456 Next